Lantern Pharma rises after early-stage trial win for its cancer drug

** Shares of drug developer Lantern Pharma LTRN.O rise 9.8% to $4.19 premarket

** Lantern Pharma says its experimental cancer drug, LP-184, met all main goals in early-stage trial, showing clean safety profile and early signs of tumor control in patients with advanced solid tumors

** Lantern reports signs of benefit in hard-to-treat cancers, including glioblastoma, gastrointestinal stromal tumors and thymic carcinoma

** Cancer indications in these targeted trials represent markets exceeding $6 billion in annual potential, LTRN says

** As of last close, LTRN stock up 19.4% YTD